Gemini Clinical Trial Site 22 — Royal Oak, Michigan

Gemini Clinical Trial Site 22 is a clinical research site located in Royal Oak, Michigan, United States 48073.

Crixeo Health Trust Score: 47/100 (POOR). This profile has not yet been claimed by the site owner.

Gemini Clinical Trial Site 22 has participated in 1 clinical trials.

Therapeutic areas: Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration.

Sponsors: Gemini Therapeutics, Inc..

Sponsor Feasibility Report

Trust Score: 47/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Gemini Clinical Trial Site 22?

Gemini Clinical Trial Site 22 has a Crixeo Trust Score of 47/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Gemini Clinical Trial Site 22 conducted?

Gemini Clinical Trial Site 22 has 1 clinical trials on record. Their work covers Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration.

Is Gemini Clinical Trial Site 22 accredited by Crixeo Health?

Gemini Clinical Trial Site 22 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Gemini Clinical Trial Site 22?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.